Aulos Bioscience Begins Phase 2 Dosing of AU-007 and Nivolumab Combo for Melanoma Immuno-oncology innovator Aulos Bioscience has initiated dosing in a new cohort of its ongoing Phase 1/2 clinical…
Mirum Receives FDA Approval for Tablet Version of LIVMARLI In a significant advancement for the rare liver disease community, Mirum Pharmaceuticals, Inc. announced today that the U.S. Food and Drug…
New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs A recently published peer-reviewed study is shedding light on the unintended yet far-reaching consequences of the Inflation…
Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company advancing novel small molecule therapeutics for immuno-oncology and hematological malignancies, announced…
AdvanCell Announces $18M MRFF Funding for Targeted Prostate Cancer Therapy AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of targeted cancer therapeutics, has received a significant boost from the Australian…
FDA Approves VYVGART Hytrulo Prefilled Syringe with ENHANZE for Self-Injection in gMG and CIDP In a major development for patients suffering from chronic neuromuscular autoimmune disorders, Halozyme Therapeutics, Inc. announced…
Vertex’s Paul Negulescu, Ph.D., Wins 2025 Gairdner Award for Cystic Fibrosis Breakthroughs In a landmark moment for both Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and the broader scientific community, Paul Negulescu,…
Bruker Enhances IR Biotyper® for Hospital Hygiene with NGS Reflex Testing At the ESCMID Global 2025 conference, Bruker’s Microbiology and Infection Diagnostics division made a major announcement regarding the expansion…
Amneal Pharmaceuticals Commits $1.5 Million to Support Parkinson’s Disease Patients During Awareness Month In a powerful show of solidarity with the Parkinson’s community, Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), a global…
FDA Approves Opdivo and Yervoy Combo as First-Line Treatment for Advanced Liver Cancer In a significant advancement for liver cancer treatment, Bristol Myers Squibb (NYSE: BMY) has announced that the…
Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML) Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing innovative therapeutics targeting diseases with high unmet…
Arcturus Therapeutics Secures FDA Fast Track Designation for ARCT-2304, a Next-Generation sa-mRNA Vaccine Targeting Pandemic Influenza A (H5N1) In a significant milestone for mRNA vaccine innovation, Arcturus Therapeutics Holdings Inc.…